MARKET

ACRX

ACRX

Acelrx Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2300
+0.0090
+4.07%
After Hours: 0.2300 0 0.00% 19:15 05/27 EDT
OPEN
0.2210
PREV CLOSE
0.2210
HIGH
0.2312
LOW
0.2150
VOLUME
876.24K
TURNOVER
0
52 WEEK HIGH
1.670
52 WEEK LOW
0.1600
MARKET CAP
33.84M
P/E (TTM)
-0.8379
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Benzinga · 3d ago
25 Stocks Moving in Tuesday's Pre-Market Session
Gainers BIMI International Medical Inc. (NASDAQ: BIMI) shares rose 136.4% to $1.43 in pre-market trading. BOQI International recently posted a Q1 loss of $0.27 per share.
Benzinga · 4d ago
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that Chief Executive Officer, Vin...
PR Newswire · 05/20 16:49
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Benzinga · 05/19 18:27
Why AcelRx Pharma Shares Are Trading Higher Today?
Benzinga · 05/19 15:57
FDA reduces certain requirements under drug safety program for AcelRx's Dsuvia
AcelRx Pharmaceuticals (NASDAQ:ACRX) on Thursday said the U.S. Food and Drug Administration (FDA) had reduced certain requirements under the drug safety program required for the company's Dsuvia treatment for acute
Seekingalpha · 05/19 14:24
BRIEF-AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA
reuters.com · 05/19 13:44
AcelRx Pharmaceuticals Provides Update On Reduced FDA REMS Requirements Related To DSUVIA
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings,
Benzinga · 05/19 12:36
More
No Data
Learn about the latest financial forecast of ACRX. Analyze the recent business situations of Acelrx Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
50.00%Buy
50.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ACRX stock price target is 4.250 with a high estimate of 4.500 and a low estimate of 4.000.
High4.500
Average4.250
Low4.000
Current 0.2300
EPS
Actual
Estimate
-0.06-0.05-0.03-0.02
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 89
Institutional Holdings: 21.33M
% Owned: 14.50%
Shares Outstanding: 147.11M
TypeInstitutionsShares
Increased
10
371.50K
New
7
192.04K
Decreased
14
2.15M
Sold Out
10
8.62M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Adrian Adams
Chief Executive Officer/Director
Vincent Angotti
Co-Founder/Director
Pamela Palmer
Chief Financial Officer
Raffi Asadorian
Other
Badri Dasu
Independent Director
Richard Afable
Independent Director
Marina Bozilenko
Independent Director
Jill Broadfoot
Independent Director
Stephen Hoffman
Independent Director
Howard Rosen
Independent Director
Mark Wan
No Data
No Data
About ACRX
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s product candidates DSUVIA, known as DZUVEO in Europe and Zalviso are both focused on the treatment of acute pain, and each utilize sufentanil, delivered via a non-invasive route of sublingual administration, exclusively for use in medically supervised settings. DSUVIA is indicates for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers and emergency departments for the management of acute pain severe enough to require an opioid analgesic. Zalviso is designed to help address certain problems associated with post-operative IV patient-controlled analgesia (PCA). Zalviso allows patients to self-administer sufentanil sublingual tablets via a pre-programmed, secure system designed in part to eliminate the risk of healthcare provider programming errors.

Webull offers kinds of AcelRx Pharmaceuticals Inc stock information, including NASDAQ:ACRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACRX stock methods without spending real money on the virtual paper trading platform.